VAV Lifesciences to supply phospholipids for mRNAbased COVID-19 vaccines

VAV Lifesciences, through its subsidiary VAV Lipids, has agreed with a US-based multinational contract development and manufacturing organisation (CDMO), to manufacture and supply highly purified synthetic phospholipids suitable for vaccine manufacturing. The CDMO will use lipids made by VAV to produce gene-based lipid nanoparticles (LNPs) on behalf of brand owners namely Pfizer-BioNTech and Moderna. VAV Lifesciences, which is headquartered in Mumbai, is the only Indian company whose lipids will be used in the mRNALNP technology-based vaccines. It will thus play a vital role in the global vaccine supply chain. The company has already initiated a commercial supply of phospholipids for largescale vaccine manufacturing through its EU cGMP certified facility under its subsidiary company, VAV Lipids, based at Ratnagiri in Maharashtra.